EZH2 and neoplasm: Importantly, treatment of ascites-derived primary cells from patients (three HGSC, one grade 2–3 endometrioid carcinoma) with HKMTI-1–005 significantly increased CXCL10 (P = 0.028), CXCL11 (P = 0.017), and CCL5 (P = 0.027) mRNA levels, compared with IFNγ stimulation alone (Fig. 2F), demonstrating that dual G9A/EZH2 inhibition may have an immunostimulatory effect in the tumor microenvironment (TME) in patients with ovarian carcinoma.